Cargando…
A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
BACKGROUND: Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed in 16%...
Autores principales: | Vakrakou, A. G., Tzanetakos, D., Valsami, S., Grigoriou, E., Psarra, K., Tzartos, J., Anagnostouli, M., Andreadou, E., Evangelopoulos, M. E., Koutsis, G., Chrysovitsanou, C., Gialafos, E., Dimitrakopoulos, A., Stefanis, L., Kilidireas, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206708/ https://www.ncbi.nlm.nih.gov/pubmed/30373566 http://dx.doi.org/10.1186/s12883-018-1183-4 |
Ejemplares similares
-
Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021) -
Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases
por: Vakrakou, Aigli G., et al.
Publicado: (2021) -
Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature
por: Vakrakou, Aigli G., et al.
Publicado: (2020) -
Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study
por: Kazakou, Paraskevi, et al.
Publicado: (2023) -
Heterogeneity of Baló’s concentric sclerosis: a study of eight cases with different therapeutic concepts
por: Tzanetakos, D., et al.
Publicado: (2020)